The optimal treatment for adult Philadelphia chromosome-negative acute lymphoblastic leukemia [Ph(−)ALL] during the first complete remission (CR1) remains a matter of debate.
One treatment option for Ph(−)ALL is autologous hematopoietic stem-cell transplantation (auto-SCT).
1,2 Previous studies have reported that the successful eradication of residual disease either before or after auto-SCT led to favorable clinical outcomes in patients with adult acute lymphoblastic leukemia (ALL) and yielded disease-free survival rates ranging from 57-77%. 3, 4 Furthermore, auto-SCT was associated with a similarly increased overall survival (OS) duration as that associated with allogeneic hematopoietic stem-cell transplantation (allo-SCT) in patients with lymphoblastic lymphoma, were analyzed ( Table 1 ). The median follow-up duration was 10 years (range: 0.02-24 years), and the 10-year OS rate was 41% (95% confidence interval (CI): 33-49%; Figure 1 ). Table S1 ). No significant factors were associated with NRM.
Patients who had undergone myeloablative preparative regimens 6 followed by allo-SCT were selected for comparison (Table 1) . With a median follow-up of 4.9 years, allo-SCT yielded a better OS rate relative to auto-SCT (63% vs. 48% at 4 years, P < 0.01).
The cumulative incidence of relapse at 4 years was higher among patients who underwent auto-SCT than among those who underwent allo-SCT [46% (95% CI: 37-54%) vs. 23%
(95% CI: 20-26%), P < 0.01]. The NRM rates at 4 years after auto-SCT and allo-SCT were 9% (95% CI: 5-14) and 16% (95% CI: 14-19), respectively (P = 0.04). With respect to the donor source, matched allo-SCT yielded a better OS than did auto-SCT, whereas auto-SCT and mismatched allo-SCT showed similar outcomes ( Figure 1) . In a multivariate analysis, autologous graft use was identified as a risk factor for relapse; however, this factor was not a significant risk factor for OS.
This study demonstrated that auto-SCT during CR1 could produce favorable outcomes in a proportion of Ph(−)ALL patients who exhibited long-term survival plateaus.
The multivariate analysis revealed that the donor source (autograft vs. allograft) was not a prognostic factor for OS. These findings appear to be encouraging. However, the current strategy has uncovered a strong trend toward omitting auto-SCT. With advances in allo-SCT methods and the improved transplant success rate, many physicians have in consensus placed the highest priority on allo-SCT as consolidation when a suitable donor is available during CR1. Besides, given the near-100% health insurance system coverage, improved coordination of the Japan Marrow Donor programs, 7 and improved outcomes from the use of pediatric-based chemotherapy regimens in adult ALL, the number of patients undergoing auto-SCT decreased rapidly in the 2000s. Approximately half of the cases in our study population were patients aged ≤24 years. The prognosis of younger patients, especially AYA patients, could be improved by the current intensive pediatric protocols. 8 Further studies are needed to compare the consolidative role of auto-SCT compared to that of chemotherapy alone.
A high relapse rate is among the main factors leading to the poorer clinical outcomes of ALL patients. 1 One important factor that has been associated with subsequent relapse is the selected conditioning regimen. TBI has been widely used as a component in the conditioning regimens of ALL patients undergoing allo-SCT. 9 In the present study, we identified TBI as a potential prognostic factor associated with reduced relapse rates in Ph(−)ALL patients who underwent auto-SCT, a finding that was consistent with those reported in earlier studies. 10 TBI might be a powerful tool for disease control along with both allo-SCT and auto-SCT. However, among mature lymphoid malignancies, the Dana-Farber group documented secondary malignancy rates of 16% at 10 years and 38% at 15 years in patients who underwent auto-SCT with TBI-based conditioning during CR1. 11 Physicians should be careful when applying TBI regimens, especially to younger patients.
Ph(−)ALL adults who benefit from allo-SCT are primarily those who present with post-induction positive MRD, whereas patients with negative MRD fare equally well with conventional chemotherapy. 12 Whether auto-SCT would be beneficial relative to chemotherapy for patients with high post-induction MRD and no suitable donor is a matter of debate. A recent meta-analysis 1 showed a lack of benefit from auto-SCT relative to treatment with chemotherapy alone. Nevertheless, no prospective studies have compared auto-SCT with chemotherapy alone in adult Ph(−)ALL patients while stratifying according to the MRD status. Recent advances in MRD detection technologies might lead to a more precise selection of transplant candidates; moreover, the use of novel agents could reduce MRD at transplantation, [13] [14] [15] which might help to expand the indications for auto-SCT.
Auto-SCT might reduce the treatment duration and, in addition, would provide relatively easily available grafts. As the optimal post-remission therapy timing is sometimes critical for adult Ph(−)ALL patients, auto-SCT during CR1 might represent a rational treatment option for some adult ALL patients. However, high relapse rates remain a well-described and significant problem among ALL patients who have undergone auto-SCT, and the prognosis of relapsed ALL is usually extremely poor. To redefine the role of auto-SCT, further investigations that compare the results of auto-SCT with those of intensive chemotherapy without stem-cell transplantation and account for the MRD status will be needed.
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